Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DRRX |
---|---|---|
09:32 ET | 554 | 1.64 |
09:52 ET | 150 | 1.6501 |
10:10 ET | 285 | 1.6801 |
10:12 ET | 128 | 1.66 |
10:14 ET | 895 | 1.69 |
10:26 ET | 189 | 1.6674 |
10:39 ET | 100 | 1.68 |
10:42 ET | 500 | 1.6886 |
11:13 ET | 500 | 1.66 |
11:47 ET | 472 | 1.65 |
12:07 ET | 2565 | 1.6691 |
12:30 ET | 215 | 1.67 |
12:41 ET | 100 | 1.68 |
12:50 ET | 2100 | 1.68 |
12:57 ET | 100 | 1.685 |
01:03 ET | 100 | 1.685 |
01:08 ET | 100 | 1.685 |
01:30 ET | 100 | 1.68 |
01:39 ET | 640 | 1.68 |
01:42 ET | 300 | 1.68 |
01:51 ET | 1000 | 1.67 |
01:57 ET | 5600 | 1.67 |
02:02 ET | 100 | 1.69 |
02:58 ET | 203 | 1.6701 |
03:02 ET | 300 | 1.6701 |
03:07 ET | 3860 | 1.67 |
03:09 ET | 442 | 1.67 |
03:12 ET | 957 | 1.67 |
03:14 ET | 500 | 1.67 |
03:18 ET | 932 | 1.67 |
03:25 ET | 2900 | 1.67 |
03:38 ET | 190 | 1.6609 |
03:57 ET | 630 | 1.67 |
03:59 ET | 1130 | 1.67 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
DURECT Corp | 51.2M | -1.9x | --- |
Atara Biotherapeutics Inc | 47.9M | -0.2x | --- |
Kezar Life Sciences Inc | 47.9M | -0.5x | --- |
LAVA Therapeutics NV | 55.5M | -1.9x | --- |
Collplant Biotechnologies Ltd | 53.6M | -7.1x | --- |
Curis Inc | 35.5M | -0.7x | --- |
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $51.2M |
---|---|
Revenue (TTM) | $8.3M |
Shares Outstanding | 31.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-0.87 |
Book Value | $0.49 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -379.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.